Majilis deputy Snezhanna Imasheva told a government hour that the cabinet should assess the potential of wild cannabis, for example for pharmaceuticals, and look at countries that make medical products from cannabis. The same debate heard that 95% of the drugs sold in Kazakhstan were from the cannabis group, with synthetics at 5% and opiates under 1%. No change to the law followed.[1]
Listed for context. No score change is recorded for Kazakhstan here.
References
- Tengrinews.kz — Депутат призвала оценить потенциал дикорастущей конопли (11 декабря 2023)Imasheva's statement at the government hour; 95% cannabis-group share.
Checked. The date and the event were compared with a source that was read.